Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two commonly used treatments, daptomycin and vancomycin, for patients with methicillin-resistant Staphylococcus aureus MRSA bloodstream infections. This open-label randomized controlled trial is a sub-study of the larger Staphylococcus aureus Network Adaptive Platform SNAP trial and aims to compare these therapies to understand their outcomes in treating MRSA bacteremia. Participants receive either daptomycin by injection at a dose decided by their treating clinician but no less than 6 mg per kg of body weight, or vancomycin by injection with dosing tailored to achieve specific blood levels based on local standards. Both treatments are given through injections, and participants are randomly assigned to one of these two groups. During the study, participants are monitored for outcomes including the desirability of their overall health status 90 days after enrollment, clinical failure, serious adverse events, death from any cause, infectious complications, and specific side effects like muscle inflammation and eosinophilic pneumonia. These outcomes are assessed within 90 days post-enrollment, with safety monitoring extending up to 42 days for certain side effects. The study involves regular assessments to evaluate these measures and ensure participant safety throughout the trial period.
Actively Recruiting
This research aims to review anonymous medical records to study the clinical outcomes of various treatments for chronic pain. It is a retrospective, multi-center data review that includes multiple patient groups to evaluate different treatment approaches. The study focuses on patients who have been implanted with or are eligible for spinal cord stimulation systems or other treatments such as radiofrequency RF or intrathecal drug delivery systems IDS. The study compares different treatment methods, including Boston Scientific devices and non-Boston Scientific systems like spinal cord stimulation, RF, and IDS. It involves two groups patients eligible for these treatments and those who have received a prior treatment followed by a different chronic pain therapy. This evaluation uses de-identified data collected from medical charts without direct patient intervention. Participants involvement consists of reviewing their past medical data over approximately two years. Researchers will measure the responder rate, which indicates the effectiveness of the treatments through the study period. Since this is a data review, there are no active treatments or visits required, and patient privacy is maintained throughout the study.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.